infertility (assisted reproduction)
Women's health · 2009–2013
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| corifollitropin alfa Controlled ovarian stimulation for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques, specifically for… | Mar 2013 | Not recommended | no section in document |
| corifollitropin alfa Controlled ovarian stimulation for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques, restricted to… | Jul 2011 | Recommended with restriction | unclear |
| corifollitropin alfa Controlled ovarian stimulation for the development of multiple follicles and pregnancy in women participating in in-vitro fertilisation techniques. | Nov 2010 | Noted | no section in document |
| ganirelix Prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive… | Nov 2009 | Recommended | no section in document |
What the PBS pays
$16M in government benefit over 2024–25, across 61,448 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ganirelix | $14.1M |
| corifollitropin alfa | $2.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.